EUVIMEDEUVIMED entdecken
Querschnittstudie

Quality of Life Assessment in Patients with Chronic Urticaria: A Cross-Sectional Comparative Study Using CU-Q²oL and DLQI Instruments

International Journal of Medicine · 20.07.2026 · 8 (7) · 898-903

DOI: 10.61336/im/26-07-128 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift International Journal of Medicine, online erschienen am 20.07.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic urticaria (CU) is a debilitating dermatological condition characterised by recurrent wheals, pruritus, and angioedema lasting more than six weeks. Beyond its physical manifestations, CU imposes a profound burden on psychological functioning, sleep quality, and social participation, thereby substantially impairing health-related quality of life (HRQoL).

Objective

To evaluate HRQoL in patients with chronic spontaneous urticaria (CSU) using validated disease-specific (CU-Q²oL) and generic dermatology (DLQI) instruments, and to identify clinical and sociodemographic predictors of impaired quality of life.

Methods

This cross-sectional comparative study enrolled 120 adult CSU patients attending a tertiary dermatology outpatient clinic and 80 age- and sex-matched healthy controls over a 12-month period. Disease severity was quantified using the Urticaria Activity Score-7 (UAS7). HRQoL was assessed using the Chronic Urticaria Quality of Life Questionnaire (CU-Q²oL) and the Dermatology Life Quality Index (DLQI). Multivariate linear regression was employed to identify independent predictors of impaired QoL.

Results

CU patients demonstrated significantly higher mean DLQI scores (12.8 ± 5.6) compared with controls (1.9 ± 2.1; p < 0.001). The mean total CU-Q²oL score was 56.7 ± 16.4. Pruritus/red raised rash (62.4 ± 18.7) and sleep disturbance (58.1 ± 20.4) were the most severely affected domains. On multivariate analysis, UAS7 severity (β = 0.61, p < 0.001), angioedema (β = 8.34, p < 0.001), anxiety/depression comorbidity (β = 11.23, p < 0.001), and disease duration >5 years (β = 6.72, p = 0.002) were the strongest independent predictors of impaired QoL. Omalizumab treatment was associated with significantly better QoL (β = −9.45, p < 0.001).

Conclusion

Chronic urticaria substantially impairs all domains of health-related quality of life. Disease severity, presence of angioedema, psychiatric comorbidity, and disease chronicity are key determinants of QoL impairment. Early aggressive disease control, coupled with psychological support and escalation to biologic therapy where indicated, is essential for optimising patient outcomes.

Zitieren

APA

(2026). Quality of Life Assessment in Patients with Chronic Urticaria: A Cross-Sectional Comparative Study Using CU-Q²oL and DLQI Instruments. International Journal of Medicine, 8(7), 898-903. https://doi.org/10.61336/im/26-07-128

Vancouver

Quality of Life Assessment in Patients with Chronic Urticaria: A Cross-Sectional Comparative Study Using CU-Q²oL and DLQI Instruments. International Journal of Medicine. 2026;8(7):898-903. doi:10.61336/im/26-07-128

BibTeX
@article{euvimed2026,
  title = {Quality of Life Assessment in Patients with Chronic Urticaria: A Cross-Sectional Comparative Study Using CU-Q²oL and DLQI Instruments},
  journal = {International Journal of Medicine},
  year = {2026},
  volume = {8},
  number = {7},
  pages = {898--903},
  doi = {10.61336/im/26-07-128}
}
Kostenlos starten →